Eli Lilly (LLY) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access LLY quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Eli Lilly balances operational cash generation with investment and financing decisions.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income20,640.00
Depreciation & amortization1,997.00
Amortization of Other Assets0.00
Write-down of identifiable intangibles0.00
Accountig change0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-4,671.00
Minority Interests0.00
Gain (Loss) on Disposition of Intangible Assets-180.00
Share-based Compensation626.00
Stockbased compensation0.00
Gains (Losses) on Extinguishment of Debt0.00
Acquired In Process Research And Development Net Of Tax-
Research And Development Asset Acquired Other Than Through Business Combination Written Off2,910.00
Income taxes620.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts and Other Receivables-7,000.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities10,187.00
Accrued expenses0.00
Postretirement benefits0.00
Increase (Decrease) in Deferred Income Taxes-8,316.00
Other Working Capital0.00
Other assets & liabilities0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities16,813.00
Investing Activities
Capital Expenditures-7,841.00
Sale of Capital Items218.00
Short-term Investments Proceeds0.00
Short-term investments acq.0.00
Proceeds from other investments0.00
Purchase Of In Process Research And Development-
Purchased In Process Research And Development-
Purchases Of In Process Research And Development-
Increase (Decrease) in Restricted Cash0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Payments to Acquire Other Investments319.00
Purchases of Long-term assets0.00
Acquisition Net of Cash Acquired-3,669.00
Investment in affiliate0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities1.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-10,972.00
Financing Activities
Short-term debt Net-4,338.00
Other borrowing transactions0.00
Long-term debt - borrowings13,167.00
Long-term debt - repayments-778.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock-4,108.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net-772.00
Proceeds from Issuanceor Sale of Equity from Subsidiary-
Dividends paid to minority interests0.00
Dividends paid-5,384.00
Net Cash Flow from Financing Activities-2,213.00
Effect of exchange rate on cash flow372.00
Discontinued operations0.00
Free Cash Flow9,190.00
Total Cash Flow4,000.00
4 historic quarters locked

Sign in to unlock the full Eli Lilly cash flow history.

About Eli Lilly and Co Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 12, 2026
  • Source: lly-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000059478-26-000013

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License